New pill takes aim at Cancer's DNA repair: first human trial begins

NCT ID NCT05055609

Recruiting now Disease control Sponsor: Trethera Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental oral drug called TRE-515 in adults with advanced solid tumors that no longer respond to standard treatments. The drug works by blocking a protein cancer cells need to make DNA, potentially slowing their growth. The main goals are to check safety, find the best dose, and get a first look at whether the drug can control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TRE-515 (an oral drug that targets a protein involved in DNA replication in cancer cells)
What this could lead to: If successful, this could lead to a new oral treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This is a very early (Phase 1) study with only 94 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects that limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ONCOLOGY SOLID TUMOR, ADULT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Carolina BioOncology Institute
RECRUITING

Huntersville, North Carolina, 28078, United States
UCLA
RECRUITING

Santa Monica, California, 90404, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.